Market Place
Sourcing Support
Personalis Appoints President To Accelerate MRD Adoption
17 Mar 2026 //
PHARMIWEB
Personalis To Present At TD Cowen 46th Healthcare Conference
17 Feb 2026 //
BUSINESSWIRE
Personalis To Report Q4 And Full Year 2025 Financial Results
12 Feb 2026 //
BUSINESSWIRE
Personalis Joins BTIG Medtech & Life Science Conference
28 Jan 2026 //
BUSINESSWIRE
Personalis Launches Real-Time MRD Tracker
12 Jan 2026 //
BUSINESSWIRE
Personalis Reports Preliminary Q4 And Full Year 2025 Results
08 Jan 2026 //
BUSINESSWIRE
Personalis to Present at Piper Sandler Healthcare Conference
18 Nov 2025 //
BUSINESSWIRE
Personalis Reports Third Quarter 2025 Financial Results
04 Nov 2025 //
BUSINESS WIRE
Personalis To Announce Third Quarter 2025 Financial Results
21 Oct 2025 //
BUSINESS WIRE
Personalis`s Inducement Grants Under Nasdaq Rule 5635(c)(4)
15 Sep 2025 //
BUSINESSWIRE
Personalis to Participate in Upcoming Investor Conferences
27 Aug 2025 //
BUSINESSWIRE
Personalis Announces Q2 2025 Financial Results
05 Aug 2025 //
BUSINESSWIRE
Personalis to Announce Second Quarter 2025 Financial Results
22 Jul 2025 //
BUSINESSWIRE
Personalis Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
18 Jul 2025 //
BUSINESSWIRE
NeXT Personal Identifies High-Risk Relapse In Breast Cancer
02 Jun 2025 //
BUSINESSWIRE
Personalis Reports First Quarter 2025 Financial Results
06 May 2025 //
BUSINESSWIRE
Personalis to Announce First Quarter 2025 Financial Results
22 Apr 2025 //
BUSINESSWIRE
Personalis to Attend 24th Annual Needham Virtual Healthcare Conf
26 Mar 2025 //
BUSINESSWIRE
Personalis to Participate at TD Cowen`s Health Care Conference
18 Feb 2025 //
BUSINESSWIRE
Personalis to Announce Q4 & Full Year 2024 Financial Results
13 Feb 2025 //
BUSINESSWIRE
Personalis Reports Q4 And Full Year 2024 Revenue
07 Jan 2025 //
BUSINESSWIRE
Personalis Advances Strategy with Merck Investment, Moderna Deal
19 Dec 2024 //
BUSINESSWIRE
Personalis and Tempus Expand Collaboration to Biopharma
16 Dec 2024 //
BUSINESSWIRE
Personalis to Participate at Upcoming Investor Conferences
22 Aug 2024 //
BUSINESSWIRE
Personalis and Tempus Announce Expanded Collaboration
16 Aug 2024 //
BUSINESSWIRE
Personalis to Announce Second Quarter 2024 Financial Results
24 Jul 2024 //
BUSINESSWIRE
Personalis To Participate At TD Cowen 3rd Annual Tools Dx Revolution Conference
18 Jun 2024 //
BUSINESSWIRE
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
13 Jun 2024 //
BUSINESSWIRE
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 May 2024 //
BUSINESSWIRE
Personalis Reports First Quarter 2024 Financial Results
08 May 2024 //
BUSINESSWIRE
Personalis to Announce First Quarter 2024 Financial Results
24 Apr 2024 //
BUSINESSWIRE
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Mar 2024 //
BUSINESSWIRE
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 2024 //
BUSINESSWIRE
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
14 Feb 2024 //
BUSINESSWIRE
Personalis and ClearNote Announce Partnership to Advance Epigenomic Technology
30 Jan 2024 //
BUSINESSWIRE
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 Jan 2024 //
BUSINESSWIRE
Personalis Announces Medicare Coverage for NeXT Dx(R)
16 Jan 2024 //
BUSINESSWIRE
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
04 Dec 2023 //
BUSINESSWIRE
Personalis Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
BUSINESSWIRE
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 Aug 2023 //
BUSINESSWIRE
Personalis Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
Personalis to Participate at Upcoming Investor Conferences
01 Aug 2023 //
BUSINESSWIRE
Personalis to Announce Second Quarter 2023 Financial Results
25 Jul 2023 //
BUSINESSWIRE
Dr. Kenneth J. Widder Joins Personalis Board of Directors
13 Jun 2023 //
BUSINESSWIRE
Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023
30 May 2023 //
BUSINESSWIRE
Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial
02 May 2023 //
BUSINESSWIRE
Personalis Announces Abstracts Accepted for Presentation at AACR Annual Meeting
22 Mar 2023 //
BUSINESSWIRE
Personalis Selected for Research After Evaluation of Disease Assay
07 Mar 2023 //
BUSINESSWIRE
Personalis Appoints Christopher Hall as Chief Executive Officer
02 Mar 2023 //
BUSINESSWIRE
Personalis Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 2023 //
BUSINESSWIRE
Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results
09 Feb 2023 //
BUSINESSWIRE
Personalis to Participate at Upcoming Investor Conferences
06 Feb 2023 //
BUSINESSWIRE
Personalis & UCSF to Study Utility of ctDNA for Treatment in Colorectal Cancer
30 Nov 2022 //
BUSINESSWIRE
Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference
21 Nov 2022 //
BUSINESSWIRE
Personalis Presents Data from New Platform Features at SITC
07 Nov 2022 //
BUSINESSWIRE
Personalis Reports Third Quarter 2022 Financial Results
02 Nov 2022 //
BUSINESSWIRE
Personalis Appoints Christopher Hall as Senior Vice President and Head
31 Oct 2022 //
BUSINESSWIRE
Personalis to Announce Third Quarter 2022 Financial Results
19 Oct 2022 //
BUSINESSWIRE
